BioCentury | Dec 30, 2016
Emerging Company Profile

Mining for substitutions

...two topical peptide-based therapeutics in the clinic for infectious disease that are not conventional antibiotics. Pergamum AB...
...National Cancer Institute (NCI), Bethesda, Md. National Eye Institute, Bethesda, Md. NovaBiotics Ltd., Aberdeen, U.K. Pergamum AB...
BioCentury | Jul 15, 2013
Clinical News

LL-37: Preliminary Phase II data

...to placebo (p<0.05), while high-dose LL-37 led to no improvement in wound healing vs. placebo. Pergamum...
...said it does not plan to finance further clinical development of LL-37 without a partner. Pergamum AB...
BioCentury | Jul 15, 2013
Clinical News

PXL-01: Additional Phase II data

...sheath and around the tendon sheath after surgery but before closure of the surgical wound. Pergamum...
..."confidence to proceed with the development" of PXL-01, but declined to disclose details. Last year, Pergamum...
...of improving TAM2 scores at week 12 post-surgery vs. placebo (see BioCentury, July 16, 2012). Pergamum AB...
BioCentury | Apr 29, 2013
Clinical News

LL-37: Phase I/II ongoing

...evaluating 3 doses of LL-37 for 1 month in 34 patients with venous leg ulcers. Pergamum AB...
BioCentury | Feb 18, 2013
Company News

Cadila Pharmaceuticals, Pergamum deal

...up to Phase II testing. The companies will share global rights to market the product. Pergamum...
...additional details. Cadila could not be reached for comment. Cadila Pharmaceuticals Ltd. , Ahmedabad, India Pergamum AB...
BioCentury | Feb 11, 2013
Company News

NeuroVive management update

...Sweden Business: Neurology Hired: Jan Nilsson, a director, as COO, formerly chief commercial officer of Pergamum AB...
BioCentury | Jan 14, 2013
Finance

Rosetta's Nordic preferences

...Mood AB ; infectious disease companies Biosergen A/S and Dilaforette AB ; and dermatology play Pergamum AB...
...NeoDynamics AB , Lidingo, Sweden Nordic Biotech , Copenhagen, Denmark NovaSaid AB , Solna, Sweden Pergamum AB...
BioCentury | Dec 24, 2012
Clinical News

DPK-060: Phase II data

...DPK-060 led to complete cure in 85-94% of patients depending on the rating scale used. Pergamum...
...in 13 of the 25 portfolio companies of Karolinska Development AB (SSE:KDEV, Solna, Sweden), including Pergamum...
...Omnio Healer AB, BioCis Pharma Ltd. and PharmaSurgics into Pergamum (see BioCentury, Sept. 14, 2009). Pergamum AB...
BioCentury | Dec 22, 2012
Financial News

Rosetta syndicate acquiring stake in Karolinska companies

...Dilafor AB , Biosergen A/S , NeoDynamics AB , Clanotech AB, Promimic AB , Pergamum AB...
BioCentury | Sep 17, 2012
Clinical News

LL-37: Phase I/II started

...Phase I/II trial to evaluate 3 doses of LL-37 for 1 month in 32 patients. Pergamum AB...
Items per page:
1 - 10 of 24
BioCentury | Dec 30, 2016
Emerging Company Profile

Mining for substitutions

...two topical peptide-based therapeutics in the clinic for infectious disease that are not conventional antibiotics. Pergamum AB...
...National Cancer Institute (NCI), Bethesda, Md. National Eye Institute, Bethesda, Md. NovaBiotics Ltd., Aberdeen, U.K. Pergamum AB...
BioCentury | Jul 15, 2013
Clinical News

LL-37: Preliminary Phase II data

...to placebo (p<0.05), while high-dose LL-37 led to no improvement in wound healing vs. placebo. Pergamum...
...said it does not plan to finance further clinical development of LL-37 without a partner. Pergamum AB...
BioCentury | Jul 15, 2013
Clinical News

PXL-01: Additional Phase II data

...sheath and around the tendon sheath after surgery but before closure of the surgical wound. Pergamum...
..."confidence to proceed with the development" of PXL-01, but declined to disclose details. Last year, Pergamum...
...of improving TAM2 scores at week 12 post-surgery vs. placebo (see BioCentury, July 16, 2012). Pergamum AB...
BioCentury | Apr 29, 2013
Clinical News

LL-37: Phase I/II ongoing

...evaluating 3 doses of LL-37 for 1 month in 34 patients with venous leg ulcers. Pergamum AB...
BioCentury | Feb 18, 2013
Company News

Cadila Pharmaceuticals, Pergamum deal

...up to Phase II testing. The companies will share global rights to market the product. Pergamum...
...additional details. Cadila could not be reached for comment. Cadila Pharmaceuticals Ltd. , Ahmedabad, India Pergamum AB...
BioCentury | Feb 11, 2013
Company News

NeuroVive management update

...Sweden Business: Neurology Hired: Jan Nilsson, a director, as COO, formerly chief commercial officer of Pergamum AB...
BioCentury | Jan 14, 2013
Finance

Rosetta's Nordic preferences

...Mood AB ; infectious disease companies Biosergen A/S and Dilaforette AB ; and dermatology play Pergamum AB...
...NeoDynamics AB , Lidingo, Sweden Nordic Biotech , Copenhagen, Denmark NovaSaid AB , Solna, Sweden Pergamum AB...
BioCentury | Dec 24, 2012
Clinical News

DPK-060: Phase II data

...DPK-060 led to complete cure in 85-94% of patients depending on the rating scale used. Pergamum...
...in 13 of the 25 portfolio companies of Karolinska Development AB (SSE:KDEV, Solna, Sweden), including Pergamum...
...Omnio Healer AB, BioCis Pharma Ltd. and PharmaSurgics into Pergamum (see BioCentury, Sept. 14, 2009). Pergamum AB...
BioCentury | Dec 22, 2012
Financial News

Rosetta syndicate acquiring stake in Karolinska companies

...Dilafor AB , Biosergen A/S , NeoDynamics AB , Clanotech AB, Promimic AB , Pergamum AB...
BioCentury | Sep 17, 2012
Clinical News

LL-37: Phase I/II started

...Phase I/II trial to evaluate 3 doses of LL-37 for 1 month in 32 patients. Pergamum AB...
Items per page:
1 - 10 of 24